
Paul Hastings LLP
paulhastings.comLawyers

Josh Zelig
- Phone(212) 318-6491
- Email[email protected]
Work Department
Partner, Corporate Department
Position
Joshua M. Zelig is a partner in the Global Finance practice of Paul Hastings and is based in the firm’s New York office.
Mr. Zelig’s practice is primarily focused on representing leading commercial and investment banks in leveraged finance and asset-based lending transactions, including bank financings and leveraged buyouts, direct lending, bridge lending and loan commitments, and debt and equity offerings. He represented the financing sources in numerous acquisition-related financings, including the investment in Cotiviti by KKR, acquisitions of Scientific Games’ Lottery Business and DexKo by Brookfield Capital, CoreLogic and Ascensus by Stone Point Capital, Rosen Group by Partners Group, Interior Logic Group, Alight Solutions and Team Health by Blackstone, the acquisition of EMC by Dell, and the purchase of Signode by Crown Holdings.
Mr. Zelig has experience practicing in a variety of industries including healthcare, financial services, media and communications, retail and food services, energy, and technology.
Mr. Zelig is recognized as a leading lawyer for Banking & Finance in New York by Chambers USA, where clients note that he is “super commercial and practical,” “technically proficient” and “a very good attorney” who is “really dedicated to his clients.” Mr. Zelig is also recognized as a “Next Generation Partner” for Capital Markets: High-Yield Debt Offerings and is recommended for Commercial Lending by The Legal 500 US. He is recognized as a “Notable Practitioner” for Banking and Capital Markets Debt and Equity by IFLR1000 US. Mr. Zelig was named one of Secured Finance Network’s “40 Under 40” in 2021.